The pharmacologic management of premenstrual dysphoric disorder

  title={The pharmacologic management of premenstrual dysphoric disorder},
  author={Andrea Rapkin and Sharon A Winer},
  journal={Expert Opinion on Pharmacotherapy},
  pages={429 - 445}
  • A. Rapkin, S. Winer
  • Published 28 January 2008
  • Medicine, Biology
  • Expert Opinion on Pharmacotherapy
Premenstrual dysphoric disorder (PMDD) is characterized by physical, affective and behavioral symptoms that are linked to the luteal phase of the menstrual cycle and relieved soon after the onset of menses. The disorder is chronic and exerts a major impact on personal relationships and occupational productivity for the estimated 6% of reproductive-aged women who fulfill strict PMDD criteria and the almost 20% of women who nearly meet these criteria. There are now various pharmacologic options… 
Premenstrual syndrome and premenstrual dysphoric disorder in adolescents.
  • Khalida Itriyeva
  • Psychology, Medicine
    Current problems in pediatric and adolescent health care
  • 2022
Diagnosis and management of premenstrual disorders
The classification of premenstrual disorders, how to measure symptoms and diagnose the condition, and effective management strategies are discussed.
Effect of Garlic (Allium sativum) Supplementation on Premenstrual Disorders: A Randomized, Double-Blind, Placebo-Controlled Trial
The findings highlight the potential effect of garlic in reducing the severity of premenstrual symptoms; therefore, the use of garlic can be considered as an alternative therapy in the prevention and treatment of pre menstrual disorders.
The Role of Reproductive Psychiatry in Women’s Mental Health
This chapter describes the emerging field of reproductive psychiatry, including training programs, opportunities for continuing education, and the basics of screening and assessment, and highlights the clinical, ethical, and legal challenges of psychopharmacology in women’s mental health, particularly in pregnant or breastfeeding women.
Gene Expression in the Hippocampus in a Rat Model of Premenstrual Dysphoric Disorder After Treatment With Baixiangdan Capsules
The impact and likely mechanism of BXD in treating PMDD and premenstrual irritability is elaborated, and it is speculated that the differentially expressed genes could participate in neuroactive ligand-receptor interactions, mitogen-activated protein kinase, calcium, and gamma-aminobutyric acid signal transduction.
What Are Women Being Exposed to? A Review of the Quality, Content and Ownership of Websites on Premenstrual Dysphoric Disorder.
  • C. Hardy, E. Sillence
  • Medicine
    Women's health issues : official publication of the Jacobs Institute of Women's Health
  • 2016
Effects of 8-OH-DPAT and NAN-190 on anxiety behavior, monoamine metabolism, and the level of sex hormones in female rats during the estrus cycle
It is found that chronic administration of 8-OH-DPAT has an anxiolytic effect in rats in estrus and proestrus, and the mechanisms of anxiety include tight interaction between the ovarian hormonal system and the serotonergic brain system.
Effects of 8-OH-DPAT and NAN-190 on Anxious-Depressive-Like Behavior of Female Rats during the Estrous Cycle
Administration of 8-OH-DPAT had no effect on anxiety level, but produced a pronounced antidepressive effect irrespective of the phase of the estrous cycle, as well as chronic administration of NAN-190 during the estrus phase, which produced an anxiogenic effect.


Symptom-Onset Treatment for Women with Premenstrual Dysphoric Disorder
The need to further evaluate symptom-onset treatment in a larger randomized clinical trial is suggested, as many women have less than a week of symptoms, and shorter treatment intervals would further reduce medication exposure and costs.
Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome.
Luteal phase treatment in women with dysphoric PMS produced significant improvements in depression, impairment, and global ratings compared with placebo and was equivalent in efficacy to sertraline given during the entire menstrual cycle.
Symptomatic Improvement of Premenstrual Dysphoric Disorder With Sertraline Treatment: A Randomized Controlled Trial
Serotonin reuptake inhibitors such as sertraline are useful therapeutic options for women with premenstrual dysphoria as reflected by symptomatic improvement and change in reported functional impairment.
Placebo-Controlled Trial Comparing Intermittent and Continuous Paroxetine in Premenstrual Dysphoric Disorder
It is indicated that the response rate when treating PMDD with SRIs is high, and that irritability is a key target symptom, and intermittent treatment was as effective as continuous treatment in reducing irritability, affect lability, and mood swings.
Venlafaxine in the Treatment of Premenstrual Dysphoric Disorder
Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder
A 24/4 regimen of drospirenone 3 mg and ethinyl estradiol 20 &mgr;g improves symptoms associated with premenstrual dysphoric disorder.
Diagnosis of premenstrual disorders.
Diagnostic criteria for premenstrual syndrome (PMS) and dysphoric disorder (PMDD) were published by the American College of Obstetricians and Gynecologists in 2000; the American Psychiatric Association had previously established very specific diagnostic criteria for PMDD.
Treatment of premenstrual syndrome with gonadotropin‐releasing hormone agonist in a low dose regimen
Premenstrual irritability and depression were significantly relieved by low dose GnRH agonist, and GnRH treatment significantly reduced premenstrual depression and irritability, however, low doses GnRH therapy is prone to induce anovulation, particularly with increasing age.
Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs.
These guidelines present practical treatment algorithms for the use of SSRIs in women with pure PMDD or severe PMS, PMDD and underlying subsyndromal clinical features of mood or anxiety, or premenstrual exacerbation of a mood/anxiety disorder.